Back to Search
Start Over
bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
- Source :
- Clinical and Translational Medicine, Vol 12, Iss 10, Pp n/a-n/a (2022)
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
Details
- Language :
- English
- ISSN :
- 20011326
- Volume :
- 12
- Issue :
- 10
- Database :
- Directory of Open Access Journals
- Journal :
- Clinical and Translational Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.047f89e8e47c40bda51c45d3610d2d4f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1002/ctm2.1086